Production of Import-Substituting Innovative Pharmaceuticals
Shareholders in Portfolio Company
Investment Started: 2011
4.10 bln rubles
Co-investment by RUSNANO1.28 bln rubles
NANOLEK is a Russian biopharmaceutical company with its own high-tech complete cycle production based on the GMP standards, which specializes in the production of import-substituting and innovative pharmaceuticals, both in-house developed and invented with the attraction of international partners, with a focus on the prevention and treatment of socially significant diseases.
The NANOLEK’s strategy is being implemented in two stages, while adhering to the state priorities for the development of the domestic pharmaceutical industry and the Pharma-2020 strategy.
At the first stage, the NANOLEK’s activity is focused on the priorities of the state policy in the field of import substitution and is aimed at localization based on the company’s production site in the Kirov Region of the production of the most popular high-tech medicines, including those never produced on the territory of the Russian Federation before.
The next stage will be introducing to market of innovative high-tech in-house developed products, the work on which is being conducted in partnership with leading Russian research institutes and progressive foreign research companies.
NANOLEK’s biomedical complex includes three independent production buildings. The plant was built from scratch and was designed for the priority areas of the company’s product portfolio:
- Production of solid dosage forms (antiretroviral therapy, oncology and cardiovascular diseases)
- Biotechnological production in syringes and vials.
11 November 2015NANOLEK Finished Clinical Studies of Inactivated Poliomyelitis Vaccine for Preventive Treatment
Portfolio Company's News
23 December 2014
26 July 2012